Evidence-Based Best Practices

Targeting NASH

Advances in the Diagnosis and Treatment of Nonalcoholic Steatohepatitis

Presented for attendees of the 68th AASLD Annual Meeting.

This activity is jointly provided by Global Education Group and Integritas Communications. 

This activity is supported by an educational grant from Allergan.

This is not an official function/event of the American Association for the Study of Liver Diseases.

Target Audience

The educational design of this activity addresses the needs of gastroenterologists, hepatologists, and other health care professionals involved in the diagnosis and treatment of nonalcoholic steatohepatitis (NASH).

Statement of Need/Program Overview

Nonalcoholic fatty liver disease (NAFLD) is a potentially progressive spectrum of liver disorders, including one of its more severe forms, nonalcoholic steatohepatitis (NASH).1 Closely associated with rising rates of obesity and metabolic syndrome, the prevalence of NAFLD and NASH continues to trend upwards, suggesting that over the next decade, patients, clinicians, and health care systems will face an exponential increase in burdens associated with this under-recognized epidemic.2-4 In addition to having a strong foundation in current best practices for NAFLD/NASH management, liver specialists must be prepared to appropriately integrate newer noninvasive diagnostic modalities into patient work-ups and have a good understanding of the mechanisms of action, latest efficacy and safety data, and potential prescribing considerations for the numerous NASH therapies currently in late-stage development.5,6 During this Interactive Exchange™ program, expert faculty will use animated illustrations to highlight clinically relevant pathways in the complex pathophysiologic mechanisms of NAFLD and NASH; discuss current recommendations on the use of liver biopsy and complementary, noninvasive modalities for NASH diagnosis and staging; interpret the latest evidence for emerging NASH treatments; and share their preferred risk-stratification strategies to predict prognoses, shape management decisions, and monitor disease progression.4-7


  1. Haas JT, et al. Pathophysiology and mechanisms of nonalcoholic fatty liver disease. Annu Rev Physiol. 2016;78:181-205.
  2. Hassan K, et al. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol. 2014;20(34):12082-12101.
  3. Estes C, et al. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2017 Aug 12 [Epub ahead of print].
  4. Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. Int J Mol Sci. 2016;17(5):774.
  5. Renelus B, Foster T. Noninvasive evaluation of nonalcoholic fatty liver disease. Clin Liver Dis. 2016;7(3):45-47.
  6. Oseini AM, Sanyal AJ. Current and future pharmacologic treatment of nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2017;33(3):134-141.
  7. Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37(suppl 1):85-89.

Learning Objectives

Upon completion of this activity, participants will be better able to:

  • Use current epidemiologic and demographic data to enhance NASH identification
  • Describe new insights into the pathophysiology of NAFLD/NASH progression that inform the development of emerging NASH therapies and biomarkers
  • Selectively employ liver biopsy and complementary noninvasive modalities for NAFLD/NASH diagnosis, staging, and monitoring
  • Discuss the emerging NASH therapies, including the combined use of agents with complementary mechanisms of action
  • Monitor patients over time for NASH progression and hepatocellular carcinoma, including proactive identification of appropriate patients for enrollment in clinical trials


7:00 PM– 7:05 PM

Welcome and Preactivity Assessment
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD

7:05 PM – 7:30 PM

Enhanced Understanding of the Progression From NAFLD to NASH and Beyond (Audience Q&A)
Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD

7:30 PM – 8:00 PM

The Challenges of Diagnosing NASH (Audience Q&A)
Mary E. Rinella, MD

8:00 PM – 8:35 PM

Emerging NASH Therapeutics (Audience Q&A)
Vlad Ratziu, MD

8:35 PM – 8:45 PM

Case Presentation & Panel Discussion: Approaches to Management and Long-term Monitoring of Patients With NASH for Fibrosis Progression and Hepatocellular Carcinoma (HCC)

8:45 PM – 8:50 PM

Postactivity Assessment

8:50 PM – 9:00 PM

Concluding Comments and Audience Q&A

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

This CME/CE activity complies with all requirements of the federal Physician Payment Sunshine Act. If a reportable event is associated with this activity, the accredited provider managing the program will provide the appropriate physician data to the Open Payments database.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Americans with Disabilities Act

Event staff will be glad to assist you with any special needs (ie, physical, dietary, etc). Please contact Katie Anderton prior to the live event at

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas do not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Register Now

Full Name *
Credentials *
You may receive up to 4 messages per live event. Terms & Privacy Policy can be found below.
Message and data rates may apply. Reply STOP to end or HELP for help.
Primary Specialty

By clicking Register, you accept our Privacy Policy.